Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.600 +0.010 (+0.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
7 Biotech Stocks to Keep on Your Clinical Radar
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
3 Top Cancer Treatment Stocks to Buy Now
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. 
Via InvestorPlace
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%). 
Via Benzinga
Why ImmunityBio Stock Is Trading Higher Thursday
The company announced insurance coverage of ANKTIVA, a immunotherapy used to treat non-muscle invasive bladder cancer that was unresponsive to other specific treatments. 
Via Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
How Is The Market Feeling About ImmunityBio?
 
Via Benzinga
Check Out What Whales Are Doing With IBRX
 
Via Benzinga
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
From ImmunityBio, Inc.
Via Business Wire
3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions
Don't be discouraged by the bears. Here are my three picks of short-squeeze stocks to buy for investors everywhere. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
From ImmunityBio, Inc.
Via Business Wire
These 3 Interesting Stocks Are Seeing Heavy Short Interest In June 2024
Economic slowdown meets short-selling speculations. Candidates for incoming market volatility are here. 
Via Talk Markets
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
From ImmunityBio, Inc.
Via Business Wire
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
In the last three months, IBRX outperformed NVDA by over 3x. 
Via Talk Markets
IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024
IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
The 3 Best Bargain Stocks to Buy in May 2024
There are several types of bargain stocks for investors to consider. Here are the three best bargain stocks to buy now. 
Via InvestorPlace
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
From ImmunityBio, Inc.
Via Business Wire
Even Worse than Gamestop? 3 Meme Stocks That Are Screaming Sells
Here are just a few of the top meme stocks to sell immediately. In fact, I wouldn't waste investment dollars on any. 
Via InvestorPlace
Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy
Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expand BCG supply. FDA-approved Anktiva plus BCG for bladder cancer. 
Via Benzinga
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
From ImmunityBio, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
From ImmunityBio, Inc.
Via Business Wire
Stocks Quietly Climb Ahead Of Central Bank Storm
The Dow Jones Industrial Average, Nasdaq Composite, and S&P 500 Index are all sporting comfortable leads this afternoon. 
Via Talk Markets
Topics Economy Stocks
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
 
Via Benzinga
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
What's Going On With ImmunityBio Stock?
ImmunityBio said the QUILT 3.055 trial shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.